Shanghai Rightongene Biotechnology Co., Ltd Executives Under Investigation by Chinese Authorities
Shanghai Rightongene Biotechnology Co., Ltd (SHA: 688217), a Chinese biopharmaceutical company, has announced that key...
Hangzhou Jianjia Medical’s Arthbot Surgical Robot Receives NMPA Approval for Orthopedic Procedures
Hangzhou Jianjia Medical Technology Co., Ltd has received marketing approval from China’s National Medical Products...
Innorna’s Herpes Zoster mRNA Vaccine IN001 Receives Clinical Trial Approval in China
Shenzhen-based Innorna Co., Ltd has announced that it has received approval from the National Medical...
BeiGene Launches Flagship US Facility in New Jersey to Expand Oncology R&D and Manufacturing
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a global biotechnology company, has announced the inauguration...
Bayer’s BAY 3375968 Receives NMPA Approval for Clinical Trial in Advanced Solid Tumors
Bayer AG (ETR: BAYN), a multinational pharmaceutical giant based in Germany, has received clinical trial...
Chipscreen’s HDAC Inhibitor Chidamide to be Tested in Combination Therapy for CRC by NMPA
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has received...
Anhui Anke Biotechnology Receives NMPA Approval for Clinical Trial of HPV-Targeting mRNA Drug AFN0328
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced that it has received...
Novogene and Becton, Dickinson Partner to Advance Single Cell Sequencing Technologies
Novogene (SHA: 688315), a genomic services and solutions provider based in Beijing and operating globally,...
Shanghai Desano and Chongqing Kangfude Partner to Establish Peptide Drug Production Base in China
Shanghai Desano Biopharmaceutical Co., Ltd, a leading biopharmaceutical company based in China, has entered into...
TowardPi Medical Partners with OCULUS Iberia to Introduce Advanced OCTA Technology to Spain
TowardPi (Beijing) Medical Technology Ltd, a Chinese medical technology company specializing in ophthalmic imaging, has...
ViiV Healthcare’s Dovato Shows Non-Inferior Efficacy and Less Weight Gain in Pivotal PASO DOBLE Study
ViiV Healthcare, the HIV-focused subsidiary majority-owned by GSK with Pfizer and Shionogi as shareholders, has...
Pfizer Launches SGD 1 Billion API Plant Expansion in Singapore, Creating 250 New Jobs
Pfizer Inc., (NYSE: PFE) a leading global pharmaceutical company, has announced the opening of an...
China’s NHSA Updates DRG/DIP Payment Reform Program with New Exclusion Mechanisms and Timelines
The National Healthcare Security Administration (NHSA) in China has issued a notification outlining several updates...
Jiangsu Hansoh’s Loxenatide Matches Dapagliflozin in Diabetes Nephropathy Clinical Trial
Jiangsu Hansoh Pharmaceutical Co., Ltd, a leading pharmaceutical company based in China, has published the...
Innovax Biotech and GSK Terminate Collaboration on Next-Generation HPV Vaccine
Xiamen Innovax Biotech Co., Ltd., a Chinese biopharmaceutical company, and GlaxoSmithKline (GSK, NYSE: GSK), a...
China’s NMPA Considers Breakthrough Designations for Xiangxue and Innostellar’s Therapies
Xiangxue Pharmaceutical Co., Ltd (SHE: 300147) and Innostellar Biotherapeutics Co., Ltd have both been noted...
Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy
Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial...
Johnson & Johnson Pursues FDA Approval for Spravato as Monotherapy for Treatment-Resistant Depression
Johnson & Johnson (J&J, NYSE: JNJ), a leading global healthcare company, is pursuing expanded approval...
WuXi AppTec Spends Over USD 360,000 on US Lobbying Amid Biosecure Act Deliberations
Endpoints News has reported that WuXi AppTec Co., Ltd, (SHA: 603259) a China-based Contract Development...
Sino Biopharm’s Subsidiary invoX Restructures, Focusing on CD137/PD-L1 Molecule FS222
UK-based biotechnology company invoX, an international subsidiary established by China-based Sino Biopharmaceutical Group in 2021,...